Art. -Nr.: HY-110063

4-IPP

(Synonyms: 4-Iodo-6-phenylpyrimidine)

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.40%
CAS. Nr.: 41270-96-6
Formel: C₁₀H₇IN₂
Molecular Weight:282.08

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

4-IPP Chemical Structure

CAS. Nr.: 41270-96-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)^[1].

IC₅₀ & Target

MIF^[1]

In Vitro

4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity^[1].
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes^[1].
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation^[1].
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner^[1].
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

BMMs
Concentration:

0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM
Incubation Time:

24 hours, 72 hours
Result:

Inhibited osteoclastogenesis in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:

BMMs
Concentration:

5 μM,10 μM, 20 μM
Incubation Time:

1 day, 3 days, 5 days
Result:

Inhibited RANKL-induced osteoclast differentiation and bone resorption.

In Vivo

4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

8-weeks-old C57BL/6J male mice^[1]
Dosage:

1 mg/kg, 5 mg/kg
Administration:

Intraperitoneal injection; every 2 days; for 8 weeks
Result:

Alleviated OVX-induced osteoporosis.

Chemical Information

CAS. Nr. 41270-96-6
Appearance Solid
Molecular Weight 282.08
Formel C₁₀H₇IN₂
Color White to yellow
SMILES

IC1=CC(C2=CC=CC=C2)=NC=N1
Synonyms

4-Iodo-6-phenylpyrimidine
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyBio/Physico-chemical AssayFlow CytometryIF

Sort by:

Journal Impact Factor

Mol Neurodegener

Early transcriptional and cellular abnormalities in choroid plexus of a mouse model of Alzheimer's disease. [Abstract]

2025 May 31;20(1):62. PMID: 40450296
Theranostics

Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer. [Abstract]

2023 Aug 18;13(13):4574-4600. PMID: 37649598

4-IPP purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 18;13(13):4574-4600. [Abstract]

4-IPP (80 mg/kg, intraperitoneal therapy). MIF inhibitors significantly inhibited the growth of gastric cancer.

4-IPP purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 18;13(13):4574-4600. [Abstract]

4-IPP (80 mg/kg, intraperitoneal therapy). Immunofluorescence revealed the infiltration level of T cells in the MIF-inhibited group and the control group.

4-IPP purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 18;13(13):4574-4600. [Abstract]

4-IPP (80 mg/kg, intraperitoneal therapy). Flow cytometry was used to analyze the proportion and cytotoxicity of CD4+ T cells in the MIF inhibitor and control groups.
J Clin Invest

Leukemia-expanded splenic CD81+ erythroblasts potentiate disease progression in mice by reshaping leukemic cell metabolism. [Abstract]

2025 Dec 15;135(24):e193082. PMID: 41392984

4-IPP purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2025 Dec 15;135(24):e193082. [Abstract]

Illustration of experimental design (top) and cell counts (bottom) of AML cells cocultured with CD81+ Erys pretreated with either 10 μM 4-IPP or DMSO (n = 5).
J Exp Clin Cancer Res

Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4+ and CD8+ T cells. [Abstract]

2025 Jan 31;44(1):33. PMID: 39891284

4-IPP purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jan 31;44(1):33. [Abstract]

4-IPP (5 mg/kg, IP, every 2 days for 15 days). In vivo, inhibition of MIF and p-STAT3 can reduce tumor size.

4-IPP purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jan 31;44(1):33. [Abstract]

4-IPP (5 mg/kg, IP, every 2 days for 15 days). Flow cytometry results demonstrate that inhibition of MIF and p-STAT3 decrease the number of CD74+ PDGFRB+ cells.
Environ Sci Technol

IodoFinder: Machine Learning-Guided Recognition of Iodinated Chemicals in Nontargeted LC-MS/MS Analysis. [Abstract]

2025 Mar 11;59(9):4530-4539. PMID: 40015982
NPJ Precis Oncol

Single-cell transcriptome analysis identifies MIF as a novel tumor-associated neutrophil marker for pancreatic ductal adenocarcinoma. [Abstract]

2025 Aug 20;9(1):293. PMID: 40835726
Leukemia

The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma. [Abstract]

2025 Aug 1. PMID: 40750676

4-IPP purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Aug 1. [Abstract]

BMMCs were treated with Dara ± inhibitors (Belimumab [BAFF], 4-IPP [MIF], and MYCi975 [MYC]) for 24 h, then co-cultured with NK-cells at an effector:target (E:T) ratio = 1:1 for 12 h. The amount of released LDH was determined using a cytotoxicity assay kit to calculate the % of lysed cells.
Neural Regen Res

Macrophage migration inhibitory factor facilitates astrocytic production of the CCL2 chemokine following spinal cord injury. [Abstract]

2023 Aug;18(8):1802-1808. PMID: 36751809
Clin Transl Med

Single-cell transcriptome analysis deciphers the CD74-mediated immune evasion and tumour growth in lung squamous cell carcinoma with chronic obstructive pulmonary disease. [Abstract]

2024 Aug;14(8):e1786. PMID: 39113235
Bone

Macrophage migration inhibitory factor promotes heterotopic ossification by mediating ROS/HIF-1α positive feedback loop and activating Wnt/β-catenin signaling pathway. [Abstract]

2025 Jan:190:117331. PMID: 39549900
Res Sq

2026 Mar 13.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (354.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5451 mL

17.7255 mL

35.4509 mL

5 mM

0.7090 mL

3.5451 mL

7.0902 mL

10 mM

0.3545 mL

1.7725 mL

3.5451 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zheng L, et al. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-κB signaling pathway. FASEB J. 2019 Jun;33(6):7667-7683. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5451 mL	17.7255 mL	35.4509 mL	88.6273 mL
	5 mM	0.7090 mL	3.5451 mL	7.0902 mL	17.7255 mL
	10 mM	0.3545 mL	1.7725 mL	3.5451 mL	8.8627 mL
	15 mM	0.2363 mL	1.1817 mL	2.3634 mL	5.9085 mL
	20 mM	0.1773 mL	0.8863 mL	1.7725 mL	4.4314 mL
	25 mM	0.1418 mL	0.7090 mL	1.4180 mL	3.5451 mL
	30 mM	0.1182 mL	0.5908 mL	1.1817 mL	2.9542 mL
	40 mM	0.0886 mL	0.4431 mL	0.8863 mL	2.2157 mL
	50 mM	0.0709 mL	0.3545 mL	0.7090 mL	1.7725 mL
	60 mM	0.0591 mL	0.2954 mL	0.5908 mL	1.4771 mL
	80 mM	0.0443 mL	0.2216 mL	0.4431 mL	1.1078 mL
	100 mM	0.0355 mL	0.1773 mL	0.3545 mL	0.8863 mL

Keywords

4-IPP

11 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

4-IPP

Immunology/Inflammation Compound Library

Covalent Screening Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Macrophage Related Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) 4-IPP

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

4-IPP

Immunology/Inflammation Compound Library

Covalent Screening Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Macrophage Related Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) 4-IPP

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

4-IPP Related Classifications

HY-110063 Related Classifications